Optimizing the Pharmacokinetics of Sonidegib in Small Bowel Syndrome and Advanced Basal Cell Carcinoma: Our Solution

Abstract

Basal cell carcinoma (BCC) is the most common cancer worldwide, with an increasing annual incidence 1,2 -In patients with advanced BCC, lesions become extensively locally invasive or metastatic, and traditional first-line surgical treatment may be contraindicated 3 • Hedgehog pathway inhibitors (HHIs) represent an alternate treatment option for patients with advanced BCC 4 -HHIs block the aberrant Hedgehog pathway activation that allows transcription of glioma-associated oncogene transcription factors and activation of target genes for tumorigenesis and angiogenesis during development of BCC (Figure 1) 5 -Most HHIs prevent Hedgehog signaling by binding to and preventing activation of transmembrane protein Smoothened 5